Solid Biosciences Doses First Patient in Phase 3 IMPACT DUCHENNE Trial Advancing SGT-003 for Duchenne Muscular Dystrophy

- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development p...

May 08, 2026 | Friday | News
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative Amid Growing Federal Support for Psychedelic Medicine Innovation

New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines Silo Pharma ta...

May 08, 2026 | Friday | News
Thermo Fisher Launches Gibco™ CTS™ DynaXS™ Single Use Bioreactor to Advance Scalable Cell Therapy Manufacturing

New Gibco™ CTS™ DynaXS™ Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical product...

May 06, 2026 | Wednesday | News
Redefining Precision Fluid Management in Cardiorenal Care

Fluid overload remains one of the most complex and costly challenges in cardiorenal care, particularly for patients who no longer respond to conventional d...

May 04, 2026 | Monday | Interview
Kytopen Corp., T-CURX GmbH, and Fraunhofer Institute for Cell Therapy and Immunology (IZI) Launch Cell Therapy Center of Excellence in Germany

Kytopen partners with T-CURX and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Würzburg and Leipzig, Germany to establish a jo...

May 01, 2026 | Friday | News
AviadoBio Ltd. Licenses Novel AAV Capsid from Apertura Gene Therapy to Advance CNS Gene Therapy Pipeline

AviadoBio Ltd. (“AviadoBio”) and Apertura Gene Therapy (“Apertura”), a biotechnology company developing next-generation AAV capsi...

April 29, 2026 | Wednesday | News
CREATE Medicines Doses First Patient in Phase 1/2 Trial of MT-304, Advancing In Vivo Multi-Immune CAR Therapy

Validates platform's ability to rapidly iterate across immune cell types Leverages novel NK and myeloid co-programming architecture to deliver coordin...

April 28, 2026 | Tuesday | News
Santhera Pharmaceuticals Wins Positive CHMP Opinion to Expand AGAMREE® Use to Younger Duchenne Patients

Santhera Pharmaceuticals (SIX: SANN)  announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA...

April 28, 2026 | Tuesday | News
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation for Pegrizeprument (VEL-101) in Heart Transplant Rejection Prevention

OSE Immunotherapeutics SA  welcomes the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S. Food and Drug Administration (FDA) h...

April 28, 2026 | Tuesday | News
Repertoire Immune Medicines Doses First Patient in Phase 1/2 Trial of Novel TCR Bispecific RPTR-1-201 for Solid Tumors

Clinical trial will evaluate safety, tolerability and antitumor activity of Repertoire's novel off-the-shelf T cell receptor (TCR) bispecific therapy as ...

April 27, 2026 | Monday | News
Atrium Therapeutics Secures $15M Milestone from Bristol Myers Squibb for First Cardiology RNA Candidate

Atrium Therapeutics, Inc. a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15...

April 27, 2026 | Monday | News
From Promise to Practice: Lance Alstodt on Advancing Scalable Stem Cell Therapies at BioRestorative Therapies, Inc.

Regenerative medicine is entering a pivotal phase, shifting from long-standing scientific promise toward practical clinical application. BioRestorative The...

April 27, 2026 | Monday | Interaction
OrganaBio and RxMP Therapeutics Forge cGMP Manufacturing Partnership for First-in-Class Hemostatic Therapy

OrganaBio, LLC ("OrganaBio"), a vertically integrated blood and cell products and services company delivering end-to-end solutions for cell and gene ther...

April 24, 2026 | Friday | News
Specialised Therapeutics Secures Australia and Singapore Approval for ZEPZELCA–Tecentriq in ES-SCLC

  ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-...

April 22, 2026 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close